SUBSCRIBE
SUBSCRIBE

Chroma Medicine, Inc.

NEWS
Catherine Stehman-Breen, CEO, Chroma Medicine/comp
Drug Development
Chroma Scores $135M for Epigenetic Editing Approach
Backed by Google Ventures, ARCH Venture Partners and more, Chroma Medicine announced the closing of a $135 million Series B financing Wednesday.
March 1, 2023
 · 
2 min read
 · 
Kate Goodwin
Business
Top Life Sciences Startups to Watch in 2023
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
December 5, 2022
 · 
15 min read
 · 
BioSpace Editorial Staff
IN THE PRESS
Press Releases
Chroma Medicine Presents Preclinical In Vivo Data Demonstrating Best-in-Class Potency and Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2024 ESC Congress
September 3, 2024
 · 
4 min read
Press Releases
Chroma Medicine Appoints Renowned RNA Scientist Melissa Moore to Board of Directors
July 19, 2024
 · 
2 min read
Business
Chroma Medicine Announces Appointment of Jenny Marlowe, Ph.D., as Chief Development Officer
May 20, 2024
 · 
2 min read
Genetown
Chroma Medicine Highlights Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
December 10, 2023
 · 
3 min read
Drug Development
Chroma Medicine Presents Preclinical In Vivo Data Showing Durable Cholesterol Reduction with a PCSK9-Targeted Epigenetic Editor at the 2023 AHA Scientific Sessions
November 11, 2023
 · 
5 min read
Genetown
Chroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
November 2, 2023
 · 
1 min read
Business
Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors
September 27, 2023
 · 
2 min read
Genetown
Chroma Medicine Presents Data Showing Specific and Durable HBV Silencing with Epigenetic Editors at the HBV International Meeting 2023
September 20, 2023
 · 
3 min read
Business
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 20, 2023
 · 
5 min read
Genetown
Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023
May 19, 2023
 · 
3 min read
Load More
AWARDS
  • NextGen Class of 2023
JOBS